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Background: The ATS (American Thoracic Society) has recommended periodic administration
of multidrug therapy, including a macrolide and one or more parenteral agents or a combina-
tion of parenteral agents, over 2e4 months, for treatment of Mycobacterium abscessus pulmo-
nary disease. However, there is little hard evidence supporting these guidelines, and
treatment outcomes have not yet been reported.
Methods: We retrospectively evaluated 41 patients with M. abscessus pulmonary disease
treated in accordance with ATS guidelines. These patients were treated empirically with multi-
drug regimens, including a macrolide and one (amikacin) or more (amikacin and cefoxitin or
imipenem) parenteral agents, over several months. Treatment outcomes were defined as
treatment success, failure, or default.
Results: Seventeen (41.5%) patients were prescribed a macrolide and one parenteral agent,
and 24 (58.5%) were prescribed a macrolide and two parenteral agents. The median duration
of parenteral and total antibiotic treatment were 230 days (range, 60e601 days) and 511 days
(range, 164e1249 days), respectively. The treatment success, failure, and default rates were
80.5% (33/41), 12.2% (5/41), and 7.3% (3/41), respectively. Four patients relapsed over 445
days (range, 0e1443 days) of follow-up. There were no significant differences in treatment
success and relapse rates between the groups receiving one and two parenteral agents.
Adverse reactions developed in 18 of 41 patients (43.9%).c Society; DILI, drug-induced liver injury; NTM, nontuberculous mycobacteria; MAC, Mycobacterium
erculosis; AFB, acid-fast bacilli; PCR, polymerase chain reaction; DST, drug susceptibility test; CXRs,
ography; MICs, minimum inhibitory concentrations.
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782 J. Lyu et al.Conclusions: Combination antibiotic therapy, including long-term (minimum 2e4 months)
parenteral drugs, as recommended by the ATS, resulted in successful treatment outcomes in
80.5% of patients with M. abscessus lung disease in Korea.
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The incidence of nontuberculous mycobacterial (NTM)
diseases has been increasing,1,2 although there are marked
geographic variabilities in the prevalence of disease and the
proportion of the various causative species.3 In Korea, Myco-
bacterium abscessus is the second most common pathogen,
afterMAC, inNTM lungdisease,and is increasing in incidence.4
M. abscessus pulmonary disease is associatedwith substantial
morbidity andmortality.M.abscessus is resistant,however, to
all conventional antituberculous agents but is susceptible to
several antibiotics, including amikacin, cefoxitin, and clari-
thromycin.2,5 Although antibiotic regimens consisting of three
or four drugs have been used, treatment is very difficult and
there are no established optimal treatment regimens showing
good long-term-outcomes.
In 1997, the American Thoracic Society (ATS) recom-
mended that patients with M. abscessus pulmonary disease
be given 2e4 weeks of combination therapy with low-dose
amikacin plus high-dose cefoxitin.6 In 2007, however, theATS
recommended that such patients should receive periodic
administration of multidrug therapy, including a macrolide
and one or more parenteral agents, or a combination of
parenteral agents, over several (2e4) months.2 However,
there is insufficient empirical evidence for these guidelines,
which were formulated based on expert opinions. No reports
substantiating the clinical efficacy of the ATS guideline
regimen for M. abscessus pulmonary disease have yet
appeared. We therefore retrospectively analyzed treatment
outcomes in patients with M. abscessus pulmonary diseases
in Korea treated according to the proposed ATS guidelines.
Methods and materials
Patients
Patients who were diagnosed with M. abscessus pulmonary
disease and who were treated based on ATS guidelines,
from January 2003 to December 2008, at the Asan Medical
Center (Seoul, South Korea) were retrospectively evalu-
ated. Patients were divided into two groups based on the
standardized treatment regimen they received: one group
had received a macrolide (clarithromycin or azithromycin)
and one (amikacin) parenteral agent at outpatient clinic
whereas the other group had been treated with a macrolide
and two (amikacin and cefoxitin or imipenem) parenteral
agents on admission. Baseline audiology and vestibular
function testing was performed on almost all patients and
regular follow-up was recommended.
Microbiological examination
Acid-fast bacilli (AFB) were cultured on Ogawa medium and
were identified as Mycobacterium tuberculosis or NTMusing the AccuProbe test (Gen-Probe Inc., San Diego, CA).
NTM species were identified using a polymerase chain
reaction-restriction fragment length polymorphism
method, based on the rpoB gene.7 The in vitro antimicro-
bial susceptibility of M. abscessus was tested using
a commercial kit (Sensititre; TREK Diagnostic Systems,
Cleveland, Ohio) and interpreted according to tentative
guidelines established by the National Committee for Clin-
ical Laboratory Standards.8 Imipenem was not included in
the DST drug panel, based on NCCLS guidelines.
Sputum conversion was defined as three consecutive
negative cultures within 6 months, with the time of
conversion defined as the date of the first negative culture.
Microbiological relapse was defined as two consecutive
positive cultures after sputum conversion.9
Radiological examination
Initial standardpostero-anterior and lateral chest radiographs
(CXRs) and computed tomography (CT) results were rean-
alyzed based on five categories: bronchiectasis and nodular
opacities, cavities, consolidation, bilateral involvement, and
multilobar involvement (3 lobes with abnormalities).
Assessment of treatment outcomes
Treatment outcomes 1 year after the initiation of anti-NTM
treatment were analyzed. Treatment outcomes were clas-
sified as treatment success, failure, and default. ‘Treatment
success’wasdefined to satisfy all of the following criteria: (1)
culture conversion; (2) clinical improvement; (3) minimum
duration of medication at least 6 months; (4) completion of
medication according to the attending physician’s decision.
Sputum conversion was defined as three consecutive nega-
tive sputum cultures within six months, with the time of
conversion defined as the date of the first negative culture. If
the patient could not expectorate sputum, it was considered
that sputum had converted to negative.9 Clinical improve-
ment was defined as an improvement in clinical symptoms
and a decrease or at least no change in abnormal shadows on
chest radiography or CT scanning. “Failure” was defined as
lack of conversion to negative sputum culture status after
treatment, and an absence of clinical improvement.
‘Default’ was defined as interruption of treatment for more
than 2 consecutive months. Relapse was defined as more
than two consecutive positive cultures after treatment
success.10 Adverse reactions were defined as events leading
to drug discontinuation because of side-effects. Drug-
induced liver injury (DILI)was defined as elevated bilirubin or
aspartate transaminase (AST) and/or alanine transaminase
(ALT) concentrations, to 3 times the upper limit of normal
in the presence of symptoms, or 5 times the upper limit of
normal in the absence of symptoms.11 Patients were exam-
ined every 2 weeks for 1 month and then every 1 month for
thewhole duration of treatment. SputumAFB smear/culture
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completion of treatment, patients were followed up clini-
cally and radiologically, and bacteriologically if necessary,
every 3e6 months.
Statistical analysis
Results are presented as means  SDs. Differences between
categorical variables were assessed using the chi-squared
test or Fisher’s exact test, as appropriate, and differences
between continuous variables were explored using the
unpaired t-test. A p value <0.05 was considered statisti-
cally significant. Multivariate analysis was not performed
because of the small sample size. All statistical analyses
were performed using SPSS Version 13 for Windows (SPSS
Inc., Chicago, IL).
Results
Baseline clinical characteristics
From January 2003 to August 2008, 112 patients were newly
diagnosed with M. abscessus pulmonary disease. Among the
112 patients, 71 patients were considered ineligible
because of the following reasons: (1) treatment not initi-
ated due to stable clinical condition (37 patients); (2) lost
to follow-up (16 patients); (3) transfer to another hospital
after diagnosis (6 patients). There were no differences in
the baseline demographic characteristics between 41
enrolled subjects and 71 excluded subjects. After excluding
71 patients, 41 (36.6%) were included in the final analysis
(Fig. 1, Table 1). Serological human immunodeficiency virus
(HIV) tests were performed on 25 patients, all with negative
results. Median patient age was 53.2  11.7 years (range,
22e77 years), and there was a preponderance of women
(31/41) and non-smokers (35/41). Nine patients had
underlying comorbidities, one each with parkinsonism,Figure 1 Flow diagram of progress through the phases of this
study. Definition of abbreviations: ATS Z American Thoracic
Society.thymoma, thyroid cancer, interstitial lung disease, diabetes
mellitus, hepatocellular carcinoma, rheumatoid arthritis,
angina pectoris, and hypertension. The predominant CT
findings were combined bronchiectasis and nodular opaci-
ties (95.1%), and cavitation (29.3%) (Table 2). Twenty-one
(51.2%) had the nodular bronchiectatic form of NTM and 8
(19.5%) had the upper lobe cavitary form.
Drug susceptibility tests (DSTs) were performed on
M. abscessus isolates recovered from 20 patients (Table 3).
Cefoxitin, amikacin, and clarithromycin were active against
most isolates, but ciprofloxacin had poor activity.
Medical treatment
Of the 41 patients, 17 (41.5%) were treated with a macrolide
and amikacin (15 mg/kg/day, maximum 1 g/day), and 24
(58.5%) were prescribed a macrolide and two parenteral
agents (amikacin and cefoxitin or imipenem). The principle
reason for selection of a single parenteral agent (amikacin)
was the inability of the patient to be admitted to hospital,
usually because he or she could not afford the admission fee
and/or because the patient was reluctant to take time away
from work. Such patients were administered amikacin once
daily via a peripherally-inserted central catheter in the
outpatient clinic. The median durations of amikacin, cefox-
itin or imipenem, and total antibiotic treatment were 230
days (range, 60e601 days), 83 days (range, 25e288 days),
and 511 days (range, 164e1249 days), respectively. In all
patients, clarithromycin (1000 mg/day) was selected as the
first choice; in five patients, clarithromycin was replaced by
azithromycin (250 mg/day) because of adverse reactions,
mainly gastrointestinal problems. In 10 patients (24.4%),
cefoxitin (10 g/day in three divided doses) was replaced by
imipenem (500 mg, three times a day) because of adverse
reactions. Doxycycline was empirically administered to 2
patients and oral fluoroquinolones to 21 (ciprofloxacin and
moxifloxacin in 18 and 3 patients, respectively) after they
had finished parenteral drug treatment.
Surgical treatment
Thirteenpatients (31.7%), 10 in the twoparenteral and 3 in the
one parenteral drug groups, underwent adjunctive surgical
resection, and 10 of these 13 patients (76.9%) successfully
completed treatment. Of the 10 culture-positive cases diag-
nosed prior to surgical resection (7 in the two parenteral and 3
in the one parenteral drug group), treatment success rates
were 72.4% (5/7) and 33.3% (1/3), respectively. The most
common indicationfor surgerywaspersistentculturepositivity
or relapse during treatment (10 patients; 76.9%) (Table 4).
Elevenpatients underwent open thoracotomyand2hadvideo-
assisted thoracoscopic surgery. Postoperative complications
occurred in four patients (30.8%), including postoperative
pneumonia in two and bronchopleural fistula and wound
dehiscence in one patient each. All patients continued anti-
biotic therapy postoperatively.
Treatment outcomes
Cultures converted to negative in 33 patients (80.5%) at
a median of 151 days (range, 13e860 days). The rate of
Table 1 Baseline clinical characteristics of 41 patients with Mycobacterium abscessus pulmonary disease.
Patient characteristics One parenteral n Z 17 (%) Two parenteral n Z 24 (%) Total n Z 41 (%) P value
Age, mean years (range) 54.4 (31e77) 52.5 (22e68) 53.2 (22e77) 0.616
Gender, female 14 (82.4) 17 (70.8) 31 (75.6) 0.397
Body mass index, kg/m2 (range) 19.7 (14.8e26.3) 19.9 (14.2e23.5) 19.8 (14.2e26.3) 0.794
Previous pulmonary tuberculosis 11 (64.7) 14 (58.3) 25 (61.0) 0.680
Never smoker 15 (88.2) 20 (83.3) 35 (85.4) 0.662
Mean FVC, % predicted (range) 82.7 (53e112) 80.1 (47e112) 81.1 (47e112) 0.669
Mean FEV1, % predicted (range) 80.8 (52e123) 84.0 (39e122) 82.8 (39e123) 0.675
Cavitary lesion 5 (29.4) 7 (29.2) 12 (29.3) 0.986
AFB smear positive 15 (88.2) 22 (91.7) 37 (90.2) 1.000
Symptoms
Cough 14 (82.4) 20 (83.3) 34 (82.9) 0.934
Sputum 15 (88.2) 18 (75.0) 34 (82.9) 0.292
Hemptysis 6 (35.3) 11 (45.8) 17 (41.5) 0.500
Dyspnea 3 (17.6) 9 (37.5) 12 (29.3) 0.169
Easy fatigability 5 (29.4) 11 (45.8) 16 (39.0) 0.288
Febrile sense 3 (17.6) 2 (12.5) 6 (14.6) 0.646
Definition of abbreviations: MAC Z M. avium complex, FVC Z Forced vital capacity, FEV1 Z Forced expiratory volume in 1 s,
AFB Z Acid-fast bacilli.
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between the one and two parenteral agent groups, or
between patients treated medically (23/28, 82.1%) and
surgically (10/13, 76.9%) (P Z 0.692).
The treatment success, failure, and default rates were
80.5% (33/41), 12.2% (5/41), and 7.3% (3/41), respectively.
Treatment success rates did not differ significantly
between the one (13/17, 76.5%) and two- (20/24, 83.3%)
parental agent groups (P Z 0.698). Median follow-up
duration after completion of treatment was 445 days
(range, 0e1443 days). During follow-up, four patients
experienced relapse, with the relapse rate seemed to be
higher in the one- (3/13, 23.1%) than in the two- (1/20, 5%)
parenteral agent groups, but this difference was not
statistically significant (p Z 0.276). The median duration
from the end of prior treatment to relapse was 523 days
(range, 202e710). There were no significant differences in
treatment success (76.9% and 82.1%) or relapse (0% and
14.3%) rates between the surgical and non-surgical groups.
One patient with an isolate resistant to both clarithromycin
and amikacin failed to convert to culture-negative status.
Adverse reactions
Adverse reactions developed in 18 patients (43.9%) and DILI
was the most frequent adverse event (Table 5). Patients
with leukopenia or DILI were usually switched from cefox-
itin to imipenem, resolving the adverse reactions. TinnitusTable 2 Baseline chest CT findings.
ChestCT findings One parenteral n Z 17 (%
Bronchiectasis and nodular opacities 17 (100)
Cavities 5 (29.4)
Bilateral involvement 15 (88.2)
Multilobar (3 lobes) 15 (88.2)
Nodular bronchiectatic form 15 (88.2)
Upper lobe cavitary form 2 (11.8)or hearing difficulties was attributable to amikacin use.
Gastrointestinal symptoms were probably caused by clari-
thromycin and these symptoms were resolved or attenu-
ated after substitution of clarithromycin by azithromycin.
Adverse reactions were significantly more frequent in the
two- than in the one parenteral agent group (62.5% vs.
17.6%, P Z 0.004) (Table 5).Discussion
Since clarithromycin became the cornerstone of oral
therapy for M. abscessus diseases, only one study evaluated
the clinical efficacy of clarithromycin-containing regimens
in patients with such lung diseases: treatment with a mac-
rolide and an initial 4 weeks of amikacin and cefoxitin
resulted in 58% sputum culture conversion rates.12 Recent
ATS guidelines, however, have recommended prolonged
duration of parenteral antibiotic use in addition to a mac-
rolide. In the previous study, parenteral drugs were given
for 1 month, a duration that did not meet ATS guidelines.12
To the best of our knowledge, our present study is the first
showing outcomes in patients with M. abscessus pulmonary
disease treated with long-term parenteral therapy
combined with a macrolide. We used parenteral drugs for
a minimum of 2e4 months and a maximum up to 20 months.
This prolonged parenteral therapy might be a reason for
a high treatment success rate (80.5%).) Two parenteral n Z 24 (%) Total n Z 41 (%) P value
22 (91.7) 39 (95.1) 0.222
7 (29.2) 12 (29.3) 0.986
21 (87.5) 36 (87.8) 0.943
20 (83.3) 35 (85.4) 0.662
17 (70.8) 32 (78.0) 0.185
7 (29.2) 9 (22.0) 0.185
Table 3 In vitro drug susceptibility results in 20 Mycobacterium abscessus isolates.
Drug Susceptible (%) MIC (mg/mL) Intermediate (%) Resistant (%) Total (%)
Amikacin 16
11 (55.0)
32
8 (40.0)
64
1 (5.0)
20 (100)
Cefoxitin 16
8 (40.0)
32e64
12 (60.0)
128
0
20 (100)
Clarithromycin 2
19 (95.0)
4 8
1 (5.0)
20 (100)
Ciprofloxacin 1
0
2
2 (10.0)
4
18 (90.0)
20 (100)
Linezolid 8
10 (50.0)
16
6 (30.0)
32
4 (20.0)
20 (100)
Tobramycin 4
1 (5.0)
8
7 (35.0)
16
12 (60.0)
20 (100)
Minimum inhibitory concentration cutoffs were adopted from National Committee for Clinical Laboratory Standards guidelines.
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especially that of the nodular bronchiectatic type, is
usually indolent and slowly progressive. The drugs of choice
are toxic and permanent cure is not guaranteed. Therefore,
only a few patients who are both symptomatic and rapidly
progressive are candidates for specific antibiotic treat-
ment. In the present study of 112 patients, no initial
treatment was commenced in 37 patients (33.0%), because
their clinical condition was stable. By comparison, 54% of
patients in the study of Jeon et al. did not receive initial
treatment. In the present work, later disease progression
was evident in eight patients (21.6%, 8/37), after exclusion
from medication. Currently, no appropriate treatment
initiation timepoint has been established for such asymp-
tomatic patients. Further studies are needed to address
this issue.
Inmost patients, cefoxitin or imipenemwas prescribed for
2e4 months and amikacin was administered for a longer
period, up to20months. Patients treatedwitheither cefoxitin
or imipenem had to be admitted as in patients because of the
need for multiply divided doses. After discharge from the
hospital, each patient was given intravenous amikacin once
daily (15 mg/kg/day, maximum 1 g/day) on an outpatient
basis. The median duration of amikacin use in the present
study was 230 days (range, 60e601 days), with amikacinTable 4 Adjunctive surgical resection in 13 patients with
Mycobacterium abscessus lung disease.
No. of patients
n Z 13 (%)
Indications for surgery
Failure of sputum conversion 7 (53.8)
Bacteriological relapse after
initial culture conversion
3 (23.1)
Complications despite
negative culture conversion
3 (23.1)
Type of surgery
Pneumonectomy 3 (23.1)
Bilobectomy 2 (15.4)
Lobectomy plus
segmentectomy
3 (23.1)
Lobectomy 5 (38.5)administered using an indwelling peripherally-inserted
central catheter. However, because of adverse events asso-
ciated with long-term intravenous amikacin use, inhalational
amikacin may be a good alternative. In one case report,
aerosolized amikacin was successfully administered to
a patient with pulmonary nontuberculous mycobacterial
disease.13 Inhalational amikacinwas unavailable for our study
and was therefore not used.
Inducible resistance to clarithromycin may explain the
poor treatment outcomes experienced by patients with
M. abscessus lung disease who were prescribed this anti-
biotic. A recent report14 differentiated M. abscessus
complex into M. abscessus and Mycobacterium massiliense,
and found that all M. abscessus isolates showed inducible
resistance to clarithromycin, whereas M. massiliense
isolates did not. Herein, we did not differentiate clinical
isolates into M. abscessus or M. massiliense. However, the
data of the report cited above suggest that about half of all
Asan Medical Center M. abscessus complex isolates are
really M. massiliense, similar to the data of Koh et al.14,15
Thus, we are of the view that the successful response to
treatment evident in the present study is not attributable
to a high proportion of M. massiliense infections, but
rather to the prolonged use of parenteral antibiotics. When
differences in the mechanisms of drug resistance are
aligned with the observed treatment outcomes, we agree
that M. abscessus complex should be further differentiated
into M. abscessus and M. massiliense; this differentiation
would be advisable even in routine practice.
The optimal duration of treatment for M. abscessus lung
diseases is not yet clear.2 After completion of amikacin
therapy, the only potentially effective oral drug is a macro-
lide. Therefore, to continuemedical treatment formore than
1 year after culture conversion, macrolide monotherapy is
currently unavoidable. There may be several options: 1)
amikacin can be given until the end of treatment as long as no
adverse events develop; 2) other oral agents with undocu-
mented efficacy can be given together with a macrolide
(fluoroquinolonemaybe a potential candidate); 3) treatment
may be viewed as complete at the time that amikacin is
terminated. Usually, this last strategy will involve a treat-
ment duration of less than 1 year after culture conversion. In
the present study, inhalational amikacinwas not available, so
the first option could not be followed. Regarding the second
Table 5 Incidence of adverse reactions (n Z 18).
Adverse reactions One parenteral n Z 17 (%) Two parenteral n Z 24 (%) Total n Z 41 (%) P value
Tinnitus or hearing difficulties 1 (5.9) 3 (12.5) 4 (9.8) 0.629
Gastrointestinal symptom 2 (11.8) 3 (12.5) 5 (12.2) 1.000
Drug-induced liver injury 1 (5.9) 6 (25.0) 7 (17.1) 0.207
Skin eruption 0 (0) 3 (12.5) 3 (7.3) 0.254
Drug fever 0 (0) 3 (12.5) 3 (7.3) 0.254
Leukopeniaa 0 (0) 2 (8.3) 2 (4.9) 0.502
Arthralgia 1 (5.9) 0 (0) 1 (2.4) 1.000
Renal toxicity 0 (0) 1 (4.2) 1 (2.4) 1.000
Total 3 (17.6) 15 (62.5) 18 (43.9) 0.004
a Leukopenia: white blood cell counts <3000/mm3.
786 J. Lyu et al.option, “holding” regimens of a macrolide plus a quinolone
have been reported to be helpful between phases of paren-
teral drug therapy.16 However, because most in vitro
susceptibility tests reveal resistance to quinolones, and little
is known about the in vivo activity of quinolones in
M. abscessus pulmonary diseases, this strategy may result in
macrolide monotherapy.13,17 In keeping with previous
studies, we observed that only 10.0% (2/20) of isolates were
susceptible to ciprofloxacin whereas 62.2%was susceptible in
Koh et al’s study. The data on in vitro DST responses to qui-
nolones differed between our current study and that of Jeon
et al., even though both evaluations were performed in the
same geographical area (Seoul, Korea) and both works
employed an identical broth microdilution method (we used
a commercial kit; Koh et al. employed an assay developed in-
house). Hence, the clinical reliability of current in vitro M.
abscessusDSTdata requires furtherevaluation.Regarding the
third option, we do not yet have sufficient information
bearing on this possibility, although we have found that, in
somepatients, culture conversion occurred very rapidly after
treatment initiation. Because of concerns that macrolide
therapy with/without a quinolone in the continuation phase
may induce macrolide resistance, the total duration of
treatment was insufficient in some patients, with 9/41
(22.1%) patients being treated for less than 1 year.
The ATS guidelines recommend that patients with focal
lung disease who can tolerate lung resection should be
treated by surgery after an initial period of antimicrobial
drug therapy. In the present study, we adhered to general
rules of good clinical practice when conducting adjuvant
surgical resection in patients with NTM pulmonary disease.
The indicated patients were those showing a poor response
to medical treatment, and complications including massive
hemoptysis, localized disease, and an adequate functional
lung reserve. In the present study, 13/41 (31.7%) of patients
underwent surgical resection. However, treatment success
rates did not differ between the surgical and non-surgical
groups, being 76.9% and 82.1%, respectively. Prospective
controlled trials are needed to assess the effectiveness of
adjuvant surgical resection combined with combination
chemotherapy.
In our study, DSTwas not available during the first half of
the study period, so combination antibiotics were chosen
empirically. DST results showed that almost all M. abscessus
isolates were susceptible to the empirically chosen antibi-
otics clarithromycin (95%), amikacin (95%), and cefoxitin(100%), making it impossible to analyze the effect of DST
results on treatment outcomes. Thesefindings are consistent
with previous results on amikacin and cefoxitin suscepti-
bility.15 However, resistance to clarithromycin was signifi-
cantly lower in our study (5.0%) than in the earlier study cited
above (26.7%). Moreover, in the latter work, susceptibility to
clarithromycin was the only significant independent
predictor of favorable microbiologic response; culture
conversion occurred in 21/33 (64%) patients without clari-
thromycin resistance and 2/12 (17%) with clarithromycin
resistance.
One of the major limitations of long-term antibiotic
therapy is adverse drug reactions. We observed adverse
reactions in 43.9% (18/41) of patients, leading to the
withdrawal of the causative drug. The most frequent
adverse reaction was DILI (17.1%, 7/41). Adverse reactions
were more frequent in the two- than in the one parenteral
drug group (62.5% and 17.6%), respectively (p < 0.05),
suggesting that the additional adverse reactions were
caused by cefoxitin. As the treatment success rates of the
two groups were similar, long-term combination therapy
with a macrolide and amikacin (especially the inhalational
form) may be the best regimen for treatment of M.
abscessus-caused lung diseases.
The present report has several limitations inherent to
retrospective and single-center studies. The number of
enrolled patients was small and the definitions of treat-
ment outcomes were arbitrarily chosen because no stan-
dardized definitions are available. Also, patient
socioeconomic status may bias selection into the one- or
two parenteral drug group. Lastly, the follow-up duration
after treatment completion was insufficient to determine
relapse rate. Therefore, further follow-up data are needed.
In conclusion, ATS recommended combined antibiotic
therapy with a macrolide and long-term use of parenteral
drug(s) resulted in successful treatment outcomes in
a significant proportion of patients with M. abscessus lung
disease. Additional studies focusing on optimal regimens
and treatment duration are needed. Also, new companion
drugs for M. abscessus are needed to further improve
treatment outcomes.Conflicts of interest
No author has a conflict of interest to disclose.
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